Aravive Investor Presentation Deck
P1b PDAC: Clinical Activity by MEC Status
ORR higher and mPFS longer in Patients who Achieve MEC
Efficacy Evaluable
Best Response
Partial Response
Stable Disease
Progressive Disease
NE
NA (no scans)
Progression-Free Survival
Censor (n), Events (n)
mPFS (95% CI)
Trough Levels
>MEC
(N=9) 1
5 (56%)
2 (22%)
0
1 (11%)
1 (11%)
Trough Levels
<MEC
(N=9) 1
1 (11%)
2 (22%)
4 (44%)
2 (22%)
0
3,6
2,7
5.6 (2.1, NE)
2.7 (1.1, 5.4)
¹ Three patients have missing C1D15 trough samples and are not evaluable by MEC status. MEC = minimum efficacious [batiraxcept]
concentration of 14.5 mg/L, NA=not applicable based on no post-baseline scan data; NE=not evaluable per RECIST V1.1 criteria due
to death & insufficient scan data
Data cutoff Sept 8, 2022View entire presentation